CEA, CA 19-9 and CA 72-4 improve the diagnostic accurary in gastrointestinal cancers

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2311-2316

  Carpelan Holmstrom M ^a   Louhimo, J ^a   Stenman, U H ^a   Alfthan, H ^a   Haglund, C ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CA 19 9; CA 242; CA 72 4; CEA; Digestive tract; Logistic regression; Neoplasm; Tumour marker

Indexed keywords

CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIGESTIVE SYSTEM CANCER; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; PANCREAS CANCER; PANCREAS DISEASE; PRIORITY JOURNAL; STOMACH CANCER;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RECURRENCE; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036339027     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and adsorption techniques
2. Physicochemical and immunochemical properties of carcinoembryonic antigen (CEA) from different tumour sources
3. Chemistry and immunology of CEA, CA 19-9 and CA 50
4. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin
5. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies
6. Measurement of a monoclonal-antibody-defined antigen (CA 19-9) in the sera of patients with malignant and nonmalignant diseases
7. Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg
8. Novel epitopes on the CA50-carrying antigen: Chemical and immunochemical studies
9. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9
10. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases
11. CA 242, a new tumour marker for pancreatic cancer: A comparison with CA 19-9, CA 50 and CEA
12. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer
13. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9
14. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies
15. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer
16. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma
17. Cancer of the colon: The influence of the no-touch isolation technique on survival rates
18. A method of comparing the areas under receiver operating characteristic curves derived from the same cases
19. Preoperative serum levels of CEA and CA 242 in colorectal cancer
20. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer
21. The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer
22. CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients
23. Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study
24. Receiving operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 19-9 and CA 72-4 in gastric cancer
25. Tumour markers in gastrointestinal cancers - EGTM recommendations
26. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results
27. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study
28. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer
29. Serum CEA testing in the post-operative surveillance of colorectal carcinoma
30. Role of follow-up in management of local recurrences of colorectal cancer: A prospective, randomized study
31. Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients
32. Serum levels of tumor-associated glycoprotein (TAG-72) in digestive cancers
33. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9
34. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases
35. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases
36. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank
37. Evaluation of a new tumor-associated antigen in pancreatic cancer
38. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer
39. Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis
40. Serum levels of cancer-associated antigen CA-195 in gastrointestinal cancers and its comparison with CA19-9
41. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer
42. Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrence
43. Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma
44. Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA)
45. Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer
46. Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states
47. Carcinoembryonic antigen assay in cancer of the colon and pancreas and other digestive tract disorders
48. Carcinoembryonic antigen(s) in liver disease. I. Clinical and morphological studies
49. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer